Shattuck Labs (NASDAQ:STTK) Upgraded at UBS Group

UBS Group upgraded shares of Shattuck Labs (NASDAQ:STTK) to a strong-buy rating in a report released on Sunday morning,Zacks reports.

Other equities analysts also recently issued research reports about the company. Wall Street Zen downgraded Shattuck Labs from a “buy” rating to a “hold” rating in a research report on Saturday, August 15th. JPMorgan Chase & Co. assumed coverage on Shattuck Labs in a report on Friday, July 24th. They set an “overweight” rating and a $10.00 target price on the stock. Wedbush raised their target price on Shattuck Labs from $11.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday, October 2nd. TD Cowen upgraded Shattuck Labs to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Leerink Partners began coverage on Shattuck Labs in a report on Monday, July 20th. They issued an “outperform” rating and a $16.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $13.70.

Shattuck Labs Trading Down 9.9%

NASDAQ:STTK opened at $5.49 on Friday. Shattuck Labs has a 1 year low of $1.70 and a 1 year high of $8.33. The firm has a 50 day moving average of $6.73 and a 200-day moving average of $6.53. The stock has a market capitalization of $550.98 million, a P/E ratio of -10.76 and a beta of 1.09.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). As a group, analysts forecast that Shattuck Labs will post -0.45 EPS for the current fiscal year.

Institutional Trading of Shattuck Labs

A number of hedge funds and other institutional investors have recently modified their holdings of STTK. Legal & General Group Plc acquired a new stake in shares of Shattuck Labs in the 2nd quarter valued at $41,000. State of Wyoming bought a new stake in shares of Shattuck Labs during the second quarter worth $151,000. OMERS ADMINISTRATION Corp raised its position in shares of Shattuck Labs by 25.7% during the first quarter. OMERS ADMINISTRATION Corp now owns 33,300 shares of the company’s stock worth $214,000 after acquiring an additional 6,800 shares during the last quarter. Hsbc Holdings PLC acquired a new position in shares of Shattuck Labs during the first quarter valued at $269,000. Finally, Bank of America Corp DE acquired a new position in shares of Shattuck Labs during the second quarter valued at $319,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to create biologic medicines that combine immune checkpoint blockade with immune-cell activation in a single therapeutic construct.

Shattuck’s pipeline has included investigational ARC fusion proteins intended to alter the tumor microenvironment and stimulate immune responses against cancer cells.